

Product liability claim of drug alleged to cause increased risk of harm denied under Class Proceedings Act

December 19, 2022

In [Palmer v. Teva Canada Ltd](#), the Ontario Superior Court of Justice denied certification, under the Class Proceedings Act, 1992 (the Act), of a proposed class action for product liability on the basis that a plaintiff who may have suffered an increased risk of harm does not have a legally viable negligence claim if that harm has not yet materialized.

Background

In Palmer, the court was asked to certify a proposed class action relating to an allegedly contaminated pharmaceutical drug. The plaintiffs were prescribed Valsartan, a drug indicated to treat high blood pressure. The defendant pharmaceutical companies manufactured and distributed the bioequivalent of Valsartan. Each defendant **subcontracted the manufacture and supply of the drug's active ingredients to a company in China.**

The plaintiffs alleged that the active ingredients supplied by this company contained certain nitrosamine compounds, and that exposure to those compounds increases the **risk of being diagnosed with cancer.** The plaintiffs ingested the defendants' allegedly contaminated Valsartan product. They sued, pleading causes of action in product liability negligence, strict liability, toxic battery, breach of consumer protection laws, breach of the **Civil Code of Québec**, breach of the Competition Act and unjust enrichment. They sought damages for psychological harm, pure economic losses and punitive damages.

Court Decision

Justice Perell dismissed the certification motion, concluding that the proposed class action did not meet the criteria for certification under the Class Proceedings Act.

First, the court rejected all of the causes of action the plaintiffs alleged. In particular, Perell J. held that the claims in product liability negligence, one for personal injury for psychological harm, the second for pure economic loss, could not be certified. While

there was “some basis in fact” that exposure to the nitrosamine compounds increased the plaintiffs’ risk of being diagnosed with cancer, the court concluded that the mere creation of this risk could not ground a successful claim in negligence. The plaintiffs needed, instead, to demonstrate that they were actually harmed by the drugs and, for the pure economic loss claim, that they were exposed to an imminent and serious threat to their person or property.

The court further found that the proposed action did not raise common issues, which is another requirement for certification under the Act. The claim for pure economic loss could not succeed because there was no compensable harm.

As for the claim of personal injury for psychological harm, most of the proposed class would not be able to demonstrate mental injury of a serious and prolonged nature. Regardless, any emotional distress upon learning of the increase risk of cancer diagnosis was connected to a fear of increased risk of potential harm, which is not compensable under Canadian law.

The court also refused to certify certain questions about causation, aggregated damages and punitive damages.

Finally, the court found that the proposed class action was not the preferable procedure for resolving the common issues and that, regardless, it would not have advanced the three purposes of class actions.

Accordingly, the court dismissed the certification motion. Further, because there were no viable causes of action, the court dismissed the action.

Key Takeaways

The Palmer decision reaffirms the need to demonstrate actual, as opposed to future harm, especially in negligence cases. Under Canadian law, the creation of risk is not by itself tortious conduct; rather, the tortfeasor must have caused actual harm to a plaintiff **in order for the plaintiff to recover. In this case, the plaintiffs’ made the “fatal” choice to seek compensation for merely an increased risk of being diagnosed with cancer.**

Perell J.’s decision also applies the law in Canada that for a claim for pure economic loss arising from negligent supply of shoddy goods, the plaintiff must demonstrate that the defect in question poses an imminent risk of physical harm to persons or property.

The decision nevertheless leaves some questions unanswered. First, could the risk of future harm be sufficient, for the purposes of a certification motion, if it is linked to a present injury? This possibility was suggested in the Ontario Superior Court of Justice decision in [Kaplan v. Casino Rama](#) and the Newfoundland and Labrador Court of Appeal’s 2010 decision in [Dow Chemical Company v. Ring, Sr.](#), citing the UK House of Lords decision in *Grieves v. F T Everard & Sons* and others.

Second, is the degree of risk relevant? In this case, the risk introduced by the contaminated drugs was low. Further, the court noted how nitrosamine compounds are found in our food, water and soil and that, even without any exposure to the **contaminated drugs, there is a 50 per cent risk of developing cancer in one’s lifetime.**

We may need to await future decisions for answers to these questions.

For more information related to disputes or class actions, please reach out to [Byron Taylor-Conboy](#) or the key contacts listed below.

Expertise

[Disputes](#)

BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](#)

BLG Offices

Calgary

Centennial Place, East Tower
520 3rd Avenue S.W.
Calgary, AB, Canada
T2P 0R3

T 403.232.9500
F 403.266.1395

Ottawa

World Exchange Plaza
100 Queen Street
Ottawa, ON, Canada
K1P 1J9

T 613.237.5160
F 613.230.8842

Vancouver

1200 Waterfront Centre
200 Burrard Street
Vancouver, BC, Canada
V7X 1T2

T 604.687.5744
F 604.687.1415

Montréal

1000 De La Gauchetière Street West
Suite 900
Montréal, QC, Canada
H3B 5H4

T 514.954.2555
F 514.879.9015

Toronto

Bay Adelaide Centre, East Tower
22 Adelaide Street West
Toronto, ON, Canada
M5H 4E3

T 416.367.6000
F 416.367.6749

The information contained herein is of a general nature and is not intended to constitute legal advice, a complete statement of the law, or an opinion on any subject. No one should act upon it or refrain from acting without a thorough examination of the law after the facts of a specific situation are considered. You are urged to consult your legal adviser in cases of specific questions or concerns. BLG does not warrant or guarantee the accuracy, currency or completeness of this publication. No part of this publication may be reproduced without prior written permission of Borden Ladner Gervais LLP. If this publication was sent to you by BLG and you do not wish to receive further publications from BLG, you may ask to remove your contact information from our mailing lists by emailing unsubscribe@blg.com or manage your subscription preferences at blg.com/MyPreferences. If you feel you have received this message in error please contact communications@blg.com. BLG's privacy policy for publications may be found at blg.com/en/privacy.

© 2024 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.